Tesamorelin is one of the most structurally interesting tools in growth-hormone-axis research. This overview explains how it is built, how it differs from other GHRH analogs, what readouts labs use, and what to verify before ordering Tesamorelin 10mg.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It contains the full 44-amino-acid GHRH sequence with one key modification: a trans-3-hexenoyl group attached to the N-terminal tyrosine. Its molecular weight is roughly 5,136 Da. That N-terminal cap was designed to make the peptide more resistant to cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly inactivates native GHRH.
How It Works at the Receptor Level
Like native GHRH, Tesamorelin binds the GHRH receptor (GHRHR), a G-protein-coupled receptor on somatotroph cells of the anterior pituitary. Receptor activation raises intracellular cAMP and drives growth hormone release in pituitary cell models. This is a different pathway from ghrelin-receptor agonists like Ipamorelin or Hexarelin, which act on GHS-R1a.
Tesamorelin vs Other GHRH Analogs
- Sermorelin: only the first 29 residues of GHRH, with no N-terminal modification, so it is cleared faster in enzymatic assays.
- CJC-1295 (no DAC): a 29-residue analog with four amino-acid substitutions for stability. See CJC-1295 DAC vs no DAC.
- Tesamorelin: keeps all 44 residues and relies on a single N-terminal lipid-like cap for stability.
Because of these differences, Tesamorelin is a useful comparator when a lab wants to test whether the C-terminal half of GHRH changes receptor behavior.
Common Experimental Readouts
- GH release from primary pituitary cells or GH-secreting cell lines
- cAMP accumulation assays in GHRHR-expressing cells
- DPP-4 stability assays comparing Tesamorelin with unmodified GHRH(1-44)
- Downstream IGF-1 measurement in preclinical models
Experimental Design Tips
Run native GHRH or Sermorelin as a reference arm so stability gains can be quantified. When pairing with a ghrelin-receptor agonist, keep a single-agent arm for each compound so synergy can be calculated. Our Tesamorelin + Ipamorelin blend is available for labs that want a pre-matched two-pathway arm, and the trade-offs are covered in CJC-1295/Ipamorelin vs Tesamorelin.
Handling a Large Peptide
At 44 residues, Tesamorelin is more prone to aggregation and adsorption than short peptides. Reconstitute gently by letting solvent run down the vial wall, swirl rather than shake, and use low-binding tubes for aliquots. Store lyophilized vials cold, dry and dark.
Pulsatility in GH-Axis Models
Growth hormone release in vivo is pulsatile, driven by the interplay of GHRH, somatostatin and ghrelin signaling. Researchers studying GHRH analogs therefore pay close attention to sampling frequency: a single time point can miss a pulse entirely. In perfused pituitary or preclinical designs, frequent sampling and area-under-the-curve analysis give a more faithful picture of how Tesamorelin compares with shorter analogs. Including a somatostatin arm can also help show whether a response depends on the GHRH receptor pathway specifically.
Documenting Your Tesamorelin Work
Record lot number, reconstitution date, solvent, stock concentration and storage temperature for every aliquot. Large peptides lose activity faster after repeated handling, so a clear aliquot log is the easiest way to rule out degradation when results drift.
Checking Quality
Mass spectrometry is especially important for a modified 44-mer: confirm the observed mass matches about 5,136 Da, which verifies that the hexenoyl cap is present. Pair that with HPLC purity (our current lot is 99.4%) and a matching lot number.
Tesamorelin FAQ
Why does Tesamorelin have a hexenoyl group? The trans-3-hexenoyl cap shields the N-terminus from DPP-4 cleavage, improving stability compared with native GHRH in enzymatic assays.
Is Tesamorelin a ghrelin mimetic? No. It acts on the GHRH receptor, while ghrelin mimetics such as Ipamorelin act on GHS-R1a.
How is it different from Sermorelin? Sermorelin is a shorter 29-residue fragment without a stabilizing cap; Tesamorelin keeps all 44 residues plus the cap.
Explore Related Research
Browse the full GH-Axis Research collection.
Research Use Only. All compounds referenced in this article are sold by Genetic Peptides USA strictly for in-vitro and laboratory research. They are not for human or animal consumption, are not drugs, foods, or cosmetics, and are not intended to diagnose, treat, cure, or prevent any disease. This article summarizes published scientific context for educational purposes and contains no dosing guidance.